Arce HAA, Villaescusa BR

Language: Spanish
References: 8
Page: 1-3
PDF size: 242.19 Kb.

Text Extraction

No abstract.

REFERENCES

1. Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 2009; 113(22): 5412-17. DOI: https://doi.org/10.1182/blood-2008-12-194241

2. Rajkumar SV. Prevention of progression in monoclonal gammopathy of undetermined significance. Clin Cancer Res. 2009; 15: 5606-08. DOI: https://doi.org/10.1158/1078-0432.CCR-09-1575

3. Fernand JP, Bridoux F, Dispenzieri A, Jaccard A. Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications. Blood. 2018;132:(14):1478-85. DOI: https://doi.org/10.1182/blood-2018-04-839480

4. Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance. Clin Lymphoma Myeloma. 2005;6(2):102-14. DOI: https://doi.org/10.3816/CLM.2005.n.036

5. Atkin C, Richter A, Sapey E. What is the significance of monoclonal gammopathy of undetermined significance? Clin Med (Lond). 2018;18:391-96. DOI: https://doi.org/10.7861/clinmedicine.18-5-391

6. Maatouk I, He S, Hummel M, Hemmer S, Hillengass M, Goldschmidt H, et al. Patients with precursor disease exhibit similar distress and mental HRQOL as patients with active myeloma. Blood Cancer J. 2019;9(2):9. DOI: https://doi.org/10.1038/s41408-019-0172-1

7. Sigurdardottir EE, Turesson I, Lund SH, Lindqvist EK, Mailankody S. The role of diagnosis and clinical follow-up of monoclonal gammopathy of undetermined significance on survival in multiple myeloma. JAMA Oncol. 2015;1:168-74. DOI: https://doi.org/10.1001/jamaoncol.2015.23

8. Kyle RA, Larson DR, Therneau TM, Dispenzieri A, Kumar S Cerhan JR, et al. Long-term follow-up of Monoclonal Gammopathy of Undetermined Significance. N Engl J Med. 2018;378(3):241-9. DOI: https://doi.org/10.1056/NEJMoa1709974